# OnCo record ibandronic-acid (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ibandronic-acid/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ibandronic-acid" ;
  schema:name "Ibandronic acid"@en ;
  schema:alternateName "Ibandronate"@en, "Boniva (osteoporosis formulation)"@en, "Bonviva"@en, "Bondronat" ;
  schema:description "Ibandronic acid (Bondronat) is a bisphosphonate available in Europe as a monthly infusion or daily tablet to prevent fractures and other bone complications in women with breast cancer that has spread to bone, and to treat cancer-related high calcium."@en ;
  schema:url <https://onco.cc/drugs/ibandronic-acid/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ibandronic_acid> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/bondronat> ;
  onco:status "approved" ;
  onco:tag "ema-list", "supportive" ;
  onco:modality "Nitrogen-containing bisphosphonate (intravenous and oral)" ;
  onco:approval "EU 1996: Tumour-induced hypercalcaemia; prevention of skeletal events in breast cancer with bone metastases (Bondronat)" ;
  onco:related <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/drugs/denosumab/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/bone-modifying-agents/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/nct02739594/>, <https://onco.cc/trials/nct00326820/>, <https://onco.cc/trials/nct00082927/> .